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ABSTRACT
Among adults in the United States, the prevalence of reduced lung function including obstructive and restrictive lung disease 
is about 20%, representing an over 40 million adults. Persons with reduced lung function often demonstrate chronic sys-
temic inflammation, such as from elevated levels of C-reactive protein. Substantial data suggests that inflammation may 
have a significant role in the association between reduced lung function and cardiovascular disease (CVD); however, how 
reduced lung function predicts CVD as risk modification remains largely unknown. Poor lung function has been shown to 
be a better predictor of all-cause and cardiac-specific mortality than established risk factors such as serum cholesterol, and 
CVD is the leading cause of mortality among those with impaired lung function. The exact mechanism of atherosclerosis is 
not clear, but persistent low grade inflammation is considered as one of the culprits in clot formation. The initial presenta-
tion of coronary heart disease is either myocardial infarction or sudden death in approximately half of the individuals. Un-
fortunately, conventional risk factor assessment predicts only 65-80% of future cardiovascular events, leaving many middle-
aged and older individuals to manifest a major cardiovascular event despite being classified low risk by the Framingham risk 
estimates. (Korean Circ J 2011;41:171-174)
KEY WORD: Respiratory function test. 
Introduction
In spite of a current evidence-based approachs to cardiovas-
cular disease (CVD) reduction, coronary heart disease (CHD) 
remains the leading cause of mortality in the industrialized 
world. Preventive strategies utilize risk assessment to identi-
fy those most likely to benefit from medical interventions to 
reduce risk for CVD events.
1) 
The Framingham Risk Score (FRS) is a global risk algori-
thm using multiple risk factors such as age, sex, smoking his-
tory, systolic blood pressure (BP), total cholesterol, and high 
density lipoprotein-cholesterol (HDL-C) to estimate 10-year 
CHD event risk in individuals not previously diagnosed with 
heart disease.
2) While FRS is widely used as a risk assessment 
tool, it is not entirely reliable in its ability to differentiate in-
dividuals regarding CVD events.
3) A subject of interest is whe-
ther various novel risk markers such as C-reactive protein 
(CRP)
4)5) or screening tests such as coronary calcium scann-
ing
6)7) can further add to the prediction of CVD events over 
global risk. Furthermore reduced lung function has been des-
cribed as risk factor, but remains unsettled.
Cardiovascular Disease and  
Inflammation
Clinical evidence accumulated since 1990 has established 
inflammatory processes as important contributors to athero-
genesis, as well as to the vulnerability of an atherosclerotic 
lesion to rupture or erosion.
4) Based on this evidence, protein 
markers of inflammation have been studied as noninvasive 
indicators of underlying atherosclerosis in apparently healthy 
individuals and of the risk of recurrent events in patients with 
established atherosclerotic vascular disease. The most exten-172   Lung Function and CVD
sively studied biomarker of inflammation in CVD is CRP, for 
which standardized high-sensitivity assays are widely avail-
able and since hs-CRP has also been shown be an indepen-
dent predictor of atherosclerosis among apparently healthy 
men and women
5) and also improves prediction of CVD risk 
over traditional risk factors,
8) measurement of hs-CRP has 
been proposed for measurement in asymptomatic intermedi-
ate risk individuals for further risk stratification.
9) Although 
it is plausible that serum CRP is a nonspecific marker that is 
increased as part of the acute phase response to inflammation, 
experimental evidence has raised the possibility that CRP is a 
direct participant in the progression of atherosclerosis and 
its clinical consequences.
10)11)
Lung Function and  
Cardiovascular Disease
Previous epidemiologic studies have shown reduced pul-
monary function to be a significant predictor of CVD,
13-16) in-
cluding CVD mortality.
17) There is also abundant literature 
describing a significant relationship between lung function 
and all-cause mortality.
18-24) Most of these studies included 
smokers in their samples and used forced expiratory volume 
in one second (FEV1) as a measure of lung function. Smok-
ing status was shown to be causally related to mortality. How-
ever, the link between poor lung function and mortality has 
also been reported in never-smokers.
23)24)
Poor lung function has been shown to be better predictor 
of all-cause and cardiac mortality than established risk fac-
tors such as serum cholesterol.
21) The cause of this relationship 
remains largely unknown, but low grade inflammation was 
present in participants with moderate and severe airflow ob-
struction and was also associated with increased risk of car-
diac injury and this may in part explain the high rates of car-
diovascular complications in chronic obstructive pulmonary 
disease (COPD).
25) There have been recommendations for 
the use of subclinical disease screening measures in interme-
diate risk individuals, such as with coronary calcium scan-
ning to be incorporated into risk stratification algorithms to 
refine the intensity of clinical management of key risk fac-
tors.
6)7)
Individuals in this risk group are often quite heterogeneous 
and with treatment guidelines that are not always clear. A 
recent study
26) shows the potential importance of pulmonary 
function assessment in risk stratification for mortality, par-
ticularly for those individuals classified into the intermediate 
FRS group.
Lung Function and Inflammation
Reduced lung function, as assessed by peak expiratory flow, 
forced vital capacity (FVC) in 1 second (FEV1) and FVC, is as-
sociated with a increase in the occurrence of vascular altera-
tions and cardiovascular morbidity and mortality in both 
smokers and non-smokers.
13)21)22) 
Recent reports showing the relation between inflammato-
ry markers of either fibrinogen or CRP to reduced lung func-
tion in cross-sectional and prospective studies make inflam-
mation a possible mechanism.
27-32) An increase in serum CRP 
over time are associated with a significant decline of lung func-
tion, consistent with hypothesis that low-grade systematic in-
flammation is associated with lung function impairment in 
young adults.
29)30)
In a large elderly cohort, baseline fibrinogen levels were in-
versely related to FEV1 and FEV1/ FVC ratio, and baseline 
CRP levels were inversely associated with FEV1 and FVC. 
Elevated fibrinogen level predicted greater longitudinal de-
clines in FEV1/FVC with increasing age, and a similar, but 
nonsignificant association was found with CRP.
27) 
Individuals with COPD are at increased risk of CVDs, os-
teoporosis, and muscle wasting. Systemic inflammation may 
be involved in the pathogenesis of these disorders. A system-
atic review was conducted of studies which reported on the re-
lationship between COPD, FEV1 or FVC, and levels of vari-
ous systemic inflammatory markers: CRP, fibrinogen, leu-
cocytes, tumor necrosis factor-α, and interleukins 6 and 8 and 
concluded that most of inflammatory markers are associated 
with reduced lung function.
33)
Reduced lung function with COPD and restrictive lung 
disease also is associated with increasing inflammatory mark-
ers such as a CRP and fibrinogen.
34) However, the relation be-
tween reduced lung function with restrictive lung disease 
and CVD has not been well established, whereas COPD has 
been well demonstrated as risk factor for CVD. COPD is be-
ing considered as systemic inflammatory disease not limited 
pulmonary system and statins have been shown to have plei-
tropic anti-inflammatory and immune modulatory effects in 
addition to their cholesterol lowing ability.
Three large prospective observational studies reported 
that patients with COPD on a statin had substantial reduction 
in both morbidity and mortality compared with those with 
COPD who were not.
35-37) In a reported non-randomized 
study of lung function screening with COPD, compared with 
those not on statins, those taking statins had a significantly 
reduced annual FEV1 decline and reduction in COPD relat-
ed hospitalization.
38-40)
The current collective evidence suggests that statins have a 
positive impact on outcomes of COPD patients. Despite the 
encouraging results, all studies reported to date have limita-
tions and should be considered as hypothesis generating only. 
There are four randomized, double blinded, placebo-con-
trolled design, clinical trials addressing the effect of statins in 
the US National Institute of Health trials registry as of 1 Jan-
uary 2009.
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Conclusion
Traditional global risk assessment for CVD is limited by 
the ability to differentiate CVD events. Reduced lung func-
tion has been described as predictor of CVD and mortality. Sys-
temic low grade inflammation has been considered as a sig-
nificant player in this association. 
There have been recommendations for the use of subclini-
cal disease screening measures in intermediate-risk individ-
uals, such as those with coronary calcium scanning, to be in-
corporated into risk stratification algorithm to refine the in-
tensity of clinical management for key risk factors. A recent 
study shows the potential importance of lung function mea-
surement in risk stratification for mortality, particularly for 
those in the intermediate FRS group. Lung function mea-
sures provide additive prediction for all-cause mortality when 
combined with traditional risk assessment using FRS, par-
ticularly in individuals at intermediate risk group.
The clinical implications of lung function measurement 
include their use in assessing risk in individuals who are at in-
termediate cardiovascular risk for targeting who may best 
benefit from therapy.
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